Transitioning from Intravenous to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease [TRAVELESS] - Concepedia

Concepedia

Publication | Open Access

Transitioning from Intravenous to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease [TRAVELESS]

DOI Full Paper Access

51

Citations

20

References

2021

Year

Esther Ventress, David Young, Sohail Rahmany, Clare Harris, Marion Bettey, Trevor Smith, Helen Moyses, Magdalena Lech, Markus Gwiggner, Richard Felwick,

Journal of Crohn s and Colitis

Abstract

Transitioning patients established on IV vedolizumab to SC appears to be safe and effective, with high patient satisfaction and multiple benefits for the health service.

References

	Year	Citations

Page 1